# High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

> **NCT00774046** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 32 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Ara-C
- **DRUG:** Mitoxantrone
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT00774046
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00774046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00774046, "High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00774046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*